Alerts will be sent to your verified email
Verify Email
NEULANDLAB
|
Neuland Laboratories
|
Gufic Biosciences
|
Alivus Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
14.95 % | 25.05 % | 25.27 % |
|
5yr Avg Net Profit Margin
|
13.18 % | 10.9 % | 20.19 % |
|
Price to Book
|
11.27 | 6.06 | 4.08 |
|
P/E
|
97.59 | 58.83 | 23.19 |
|
5yr Avg Cash Conversion Cycle
|
38.21 Days | 26.94 Days | 100.66 Days |
|
5yr Average Interest Coverage Ratio
|
20.78 | 13.1 | 371.82 |
|
5yr Avg ROCE
|
17.63 % | 27.25 % | 33.88 % |
|
5yr Avg Operating Profit Margin
|
21.01 % | 18.45 % | 29.64 % |
|
5 yr average Debt to Equity
|
0.15 | 0.51 | 0.0 |
|
5yr CAGR Net Profit
|
26.4 % | 14.26 % | 6.67 % |
|
5yr Average Return on Assets
|
9.87 % | 11.52 % | 14.28 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
32.68 % | 72.52 % | 74.94 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-3.54 % | -2.48 % | -7.91 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
6.87 % | 2.35 % | 3.35 % |
|
Neuland Laboratories
|
Gufic Biosciences
|
Alivus Life Sciences
|
|---|